Osteoarthritis, colloquially known as “wear-and-tear arthritis”, is the most common form of arthritis, frequently affecting the joints of the hands, feet, knees, hips and spine. It involves degeneration of articular cartilage, which exposes the underlying subchondral bone, resulting in sclerosis and subsequent bone remodelling which ultimately leads to a narrowing of the joint space.
Pain and loss of function are the hallmark symptoms of osteoarthritis. Swelling and stiffness of the affected joint is often apparent, with enlargement of the fingers around the interphalangeal joints particularly common where the hands are affected.
First-line treatment for osteoarthritis involves non-pharmacological methods, with a particular focus on education and encouraging weight loss among overweight patients. This may be supplemented with analgesics and NSAIDs as required. In some cases, intra-articular corticosteroid injections provide short term pain relief, and where conservative therapy proves ineffectual, surgery may also be considered.
To find out more about Osteoarthritis, visit our Learning Zone, which contains further information on the management of this condition.
Related news and insights
Pacira BioSciences, Inc. the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash.
Bone Therapeutics announced that the Phase III knee osteoarthritis study with its enhanced viscosupplement JTA 004 (hyaluronic acid + analgesic + antiinflammatory) did not meet the primary and consequently the key secondary endpoints. The primary objective of the JTA-004 Phase III study was to demonstrate the efficacy of JTA 004 in reducing osteoarthritic knee pain compared to placebo as measured by the WOMAC pain subscale three months after treatment. A key secondary objective was the comparison between JTA 004 and comparator Hylan G-F 20 in knee pain relief at month 3.